RAAS modulation to prevent acute lung injury with COVID-19

Inspiration As a clinician, I understand that the vast increasing number of critically ill patients with COVID-19 is far away from being contained by whatever emergency plans or provision of more ventilators. Thus, it is a main target to make control the course of the disease and make it more smooth, avoiding the cytokine storm and acute lung injury. Thus, most of cases will not be in need for mechanical ventilation and the pressure on systems will be minimized. The virus binds to ACE-2 receptors and thus the course of disease is related to this fact. Modulating RAAS system by many of the well known and approved drugs or biological peptides may show significant results.

What it does modulating RAAS using biologically active peptides may interfere with the pathogenesis of the cytokine storm. The symptoms will be mild then.

How I built it We conducted a thorough review of the current literature and could find a very significant association between RAAS intermediates and the symptomatology and characteristics of COVID-19.

Challenges I ran into I was a team member in the SensUs-2017 competition- Eindhoven and we could manage to develop a point of care device for instant diagnosis of heart failure based on biologically active peptides.

Accomplishments that I'm proud of

What I learned

What's next for RAAS modulation to prevent acute lung injury with COVID-19

I need support to start a clinical trial with RAAS modulation to prove its safety and effeciency.